Delcath Systems, Inc. (DCTH)
- Previous Close
5.26 - Open
5.29 - Bid 5.26 x 100
- Ask 5.31 x 300
- Day's Range
5.28 - 5.50 - 52 Week Range
2.25 - 7.99 - Volume
110,200 - Avg. Volume
214,266 - Market Cap (intraday)
134.828M - Beta (5Y Monthly) 0.60
- PE Ratio (TTM)
-- - EPS (TTM)
-2.94 - Earnings Date May 10, 2024 - May 14, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
18.40
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.
www.delcath.comRecent News: DCTH
Performance Overview: DCTH
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: DCTH
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: DCTH
Valuation Measures
Market Cap
133.81M
Enterprise Value
111.54M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
41.34
Price/Book (mrq)
8.48
Enterprise Value/Revenue
54.02
Enterprise Value/EBITDA
-2.42
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-84.51%
Return on Equity (ttm)
-616.55%
Revenue (ttm)
2.06M
Net Income Avi to Common (ttm)
-47.68M
Diluted EPS (ttm)
-2.94
Balance Sheet and Cash Flow
Total Cash (mrq)
32.45M
Total Debt/Equity (mrq)
47.93%
Levered Free Cash Flow (ttm)
-12.43M